AlphAIAlphAI — Financial news for AI agents
tradingview.com$IBIO

IBIO Q1'27 Earnings: revenue estimate is 25.00K USD

iBio, Inc. (IBIO) will report Q1'27 earnings on November 17, with revenue estimated at $25,000 and EPS at -$0.07. The exact time of the announcement is not specified.

Original reporting
tradingview.com
Published Nov 10, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IBIO Q1'27 Earnings: revenue estimate is 25.00K USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$IBIOBearishMed
01

Why it matters

The preview provides the first public guidance, setting market expectations ahead of the earnings call.

02

Market read

Guidance sets the tone for the upcoming earnings, influencing short‑term trading decisions.

03

What to watch

Potential upcoming clinical trial milestones not mentioned could offset low revenue guidance.

Relevance 6/10Novelty 7/10Timing: pre‑market on Nov 17

Background

iBio Inc. is a small biotech listed on NASDAQ, awaiting its Q1'27 earnings release.

Company-level read

Ticker impact

$IBIOBearishMedium confidence
Context

IBIO's Q1'27 earnings preview provides revenue estimate of $25K and EPS of $0.07, disclosed for the first time.

Expected impact

likely pressure as the market prices in the low guidance

Evidence & confidence

Small revenue forecast suggests limited growth; investors may sell ahead of the actual release.

Market effects

Sector

Biotech sector may see modest impact; peers with similar guidance could experience comparable sentiment.

Regional

US biotech micro‑caps may see slight pullback.

Global

Limited to niche biotech investors.

Counterpoint

What could challenge this read

Guidance may be overly conservative; actual results could beat expectations, offering upside.

Key entities

  • Company
    iBio Inc.

    Biotech firm reporting Q1'27 earnings.

Read at source← All news

Related articles

$IBIOMed

Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose p

SEC EDGAR 8-K
$IBIOMed

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone

iBio, Inc. (IBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, vers

SEC EDGAR 8-K
$IBIOMedAI 8/10

iBio reports muscle preservation data for obesity drug candidate

iBio Inc. (IBIO) reported preclinical data showing its obesity drug candidate, IBIO-610, combined with semaglutide, preserved lean mass and increased fat loss in obese non-human primates. The study found a 97% reduction in Activin E levels and a 33.2-day half-life for the antibody. The company plans to start human trials in 2027. According to the CEO, the data suggests potential for improved weight loss quality. iBio is a clinical-stage biotech firm focusing on obesity and related diseases.

investing.com
$IBIOMed

iBio, Inc. (IBIO): Results of Operations and Financial Condition

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

SEC EDGAR 8-K
$IBIOMedAI 9/10

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.

manilatimes.net